Assessment of joint and fascia manifestations in chronic graft-versus-host disease

Arthritis and Rheumatology

Volumn 66, Issue 4, 2014, Pages 1044-1052

  Inamoto, Yoshihiro ^a   Pidala, Joseph ^b   Chai, Xiaoyu ^a   Kurland, Brenda F ^a,l   Weisdorf, Daniel ^c   Flowers, Mary E D ^a   Palmer, Jeanne ^d   Arai, Sally ^e   Jacobsohn, David ^f   Cutler, Corey ^g   Jagasia, Madan ^h   Goldberg, Jenna D ⁱ   Martin, Paul J ^a   Pavletic, Steven Z ^j   Vogelsang, Georgia B ^k   Lee, Stephanie J ^a   Carpenter, Paul A ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^f CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j NATIONAL INSTITUTES OF HEALTH   (United States)

^k JOHNS HOPKINS HOSPITAL   (United States)

^l UNIVERSITY OF PITTSBURGH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTHROPATHY; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL EVALUATION; FASCIA DISEASE; FEMALE; GRIP STRENGTH; HOPKINS FASCIA SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NATIONAL INSTITUTES OF HEALTH JOINT/FASCIA SCALE; PHOTOGRAPHIC RANGE OF MOTION SCALE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANGE OF MOTION; SYMPTOM ASSESSMENT; WALKING;

ADOLESCENT; ADULT; FASCIA; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; JOINTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; RANGE OF MOTION, ARTICULAR; SEVERITY OF ILLNESS INDEX;

EID: 84898634030     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38293     Document Type: Article

References (26)

1. Thomas E, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975; 292: 832-43.
2. Lee SJ, Vogelsang G, Flowers ME,. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215-33.
3. Van den Bergh V, Tricot G, Fonteyn G, Dom R, Bulcke J,. Diffuse fasciitis after bone marrow transplantation. Am J Med 1987; 83: 139-43.
4. Janin A, Socie G, Devergie A, Aractingi S, Esperou H, Verola O, et al. Fasciitis in chronic graft-versus-host disease: a clinicopathologic study of 14 cases. Ann Intern Med 1994; 120: 993-8.
5. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005; 11: 945-56.
6. Jacobsohn DA, Chen AR, Zahurak M, Piantadosi S, Anders V, Bolanos-Meade J, et al. Phase II study of pentostatin in patients with corticosteroid- refractory chronic graft-versus-host disease. J Clin Oncol 2007; 25: 4255-61.
7. Carpenter PA,. How I conduct a comprehensive chronic graft-versus-host disease assessment. Blood 2011; 118: 2679-87.
8. Lee S, Cook EF, Soiffer R, Antin JH,. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8: 444-52.
9. Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 2000; 89: 1634-46.
10. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-9.
11. McHorney CA, Ware JE Jr, Raczek AE,. The MOS 36-Item Short-Form Health Survey (SF-36). II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247-63.
12. Herzberg PY, Heussner P, Mumm FH, Horak M, Hilgendorf I, von Harsdorf S, et al. Validation of the Human Activity Profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 1707-17.
13. Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006; 12: 252-66.
14. The Chronic GVHD Consortium. Rationale and design of the Chronic GVHD Cohort Study: improving outcomes assessment in chronic GVHD. Biol Blood Marrow Transplant 2011; 17: 1114-20.
15. Waters RL, Lunsford BR, Perry J, Byrd R,. Energy-speed relationship of walking: standard tables. J Orthop Res 1988; 6: 215-22.
16. Mathiowetz V, Weber K, Volland G, Kashman N,. Reliability and validity of grip and pinch strength evaluations. J Hand Surg Am 1984; 9: 222-6.
17. Fitzmaurice N, Laird N, Ware J,. Applied longitudinal analysis. Hoboken (NJ): John Wiley & Sons; 2004.
18. Gardiner JC, Luo Z, Roman LA,. Fixed effects, random effects and GEE: what are the differences? Stat Med 2009; 28: 221-39.
19. Arora M, Klein JP, Weisdorf DJ, Hassebroek A, Flowers ME, Cutler CS, et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood 2011; 117: 6714-20.
20. Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988; 72: 546-54.
21. Wingard JR, Piantadosi S, Vogelsang GB, Farmer ER, Jabs DA, Levin LS, et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 1989; 74: 1428-35.
22. Vigorito AC, Campregher PV, Storer BE, Carpenter PA, Moravec CK, Kiem HP, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009; 114: 702-8.
23. Martires KJ, Baird K, Steinberg SM, Grkovic L, Joe GO, Williams KM, et al. Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. Blood 2011; 118: 4250-7.
24. Inamoto Y, Storer BE, Petersdorf EW, Nelson JL, Lee SJ, Carpenter PA, et al. Incidence, risk factors and outcomes of sclerosis in patients with chronic graft-versus-host disease. Blood 2013; 121: 5098-103.
25. Inamoto Y, Chai X, Kurland BF, Cutler C, Flowers ME, Palmer JM, et al. Validation of measurement scales in ocular graft-versus-host disease. Ophthalmology 2012; 119: 487-93.
26. Jacobsohn DA, Kurland BF, Pidala J, Inamoto Y, Chai X, Palmer JM, et al. Correlation between NIH composite skin score, patient reported skin score and outcome: results from the Chronic GVHD Consortium. Blood 2012; 120: 2545-52.